Usa

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Healthcare professionals and consumers are directed to report any adverse events related to the use of ZUBB Dietary Supplement to the FDA's MedWatch Program.

Update product labeling to include new efficacy data and boxed warnings, incorporate the new treatment into compliance protocols, and increase monitoring for adverse events associated with Etcamah.

Update labeling and monitoring protocols to include new prescribing information, dosage guidelines, and risk communications related to the potential cardiac risks associated with camizestrant.

Healthcare providers and compounding facilities should implement the new temporary policies under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act to ensure compliance and access to essential nutrition products.

Regulatory Affairs must implement the new compounding policies immediately to ensure compliance and mitigate risks associated with product availability.

Update product labels to include prevention indications for Capstar and Nitenpyram Tablets. Ensure that labeling reflects new usage guidelines for these products as outlined in the Emergency Use Authorization.

Review compliance with PREA obligations, prepare responses to any received non-compliance letters, and ensure any necessary deferral extension requests are properly submitted within the specified timeframe.

All customers handling Infinion CX Leads must stop using these devices, segregate them, and return them to Boston Scientific as per the recall protocol communicated on June 17, 2026.

Facilities must ensure that appropriate alternative monitoring is established for patients before performing software updates and include the User Manual addendum with the equipment.

Users must carefully inspect the VentStar Resus Neo hoses for damages as per the product's Instructions for Use (IFU) and discard any hoses showing signs of cracks or detachments before use.

Immediate quarantine and destruction of all affected lots are mandated. Affected inventory must be checked, and customers must be notified if products have been resold or transferred.

Healthcare providers must implement the new administration protocol for Zanvastro, which is an injection every three months, and monitor for common side effects such as vomiting, back pain, and signs of aseptic meningitis.

Enhanced monitoring for products with hidden drug ingredients is required, leading to increased need for rapid reporting and investigation of adverse events associated with similar products.

Focus on therapeutic equivalence evaluations for generics

Affected healthcare facilities and distributors must immediately check their stock, remove BD ChloraPrep applicators from all kits, apply over-labels indicating the need for component removal, and notify any customers if they have transferred or resold these products.

Affected users must identify, segregate, and quarantine the kits, add warning labels, and ensure the removal of the recalled components prior to use.

Healthcare providers must utilize updated labels and ensure phosphate levels are monitored in at-risk patients and those receiving repeat therapy within three months.

Companies preparing 510(k) submissions for dental composite resin devices must align with the recommendations specified in the new guidance, which include detailed testing and labeling criteria.

Manufacturers should align their premarket submissions for dental curing lights with the updated FDA guidance, ensuring to follow new recommendations on device description, performance testing, and labeling.

Healthcare providers and distributors must immediately identify and quarantine affected products before destroying them after completing the recall actions. Compliance with FDA recall procedures is mandatory.

Implementation of new dosing schedules and an emphasis on monitoring for potential adverse reactions as outlined in the prescribing information.

Regulatory compliance processes may need updates to incorporate the new recombinant endotoxins testing method and guidelines established under the ICMRA framework.

Patients will be treated with an initial dose of 19 mg of Mimrylo, administered weekly, with careful monitoring to maintain hematocrit levels below 45%. The operation of post-marketing surveillance will be affected due to the introduction of this new drug.

Update labeling to reflect the new indication for Stelara, and ensure compliance with associated regulatory activities including safety monitoring.

Labeling and risk management updates are required to reflect the new drug approval, including the incorporation of safety and efficacy data from the VERIFY trial.

Customers are required to quarantine affected kits, complete response forms, and destroy the kits. Notification must also be sent to distributors who should inform their customers of these updated actions.

Health care professionals must complete and return the enclosed Reply Verification Tracking Form (RVTF) indicating the quantities of affected units to return, and monitor patients following the standard of care while discontinuing the use of these catheters.

Compounding pharmacies must verify that all components used in injectable drugs are suitable for their intended use and discontinue the use of any glutathione labeled for dietary supplement purposes, particularly if sourced from Medisca.

Update product labeling to include Lisraya as the first oral treatment for dermatomyositis, ensuring that all marketing and educational materials reflect its approval and associated safety information.

Review and update internal compliance and reporting workflows to align with the FDA's reporting requirements for the latest oncology product approvals.

Cattle producers must administer Bimectin injection within specified timelines (24 hours post-birth, at castration, or on wound appearance) and observe a 35-day withdrawal period before slaughter to prevent drug residues in food.

All impacted products must be identified, segregated, and quarantined. Users are required to add appropriate warning labels and must exercise extreme caution if using the Manifolds is unavoidable.

Customers must immediately identify and quarantine all unused affected devices (Bravo CF capsule delivery devices, product numbers FGS-0635 and FGS-0636) and return them to Medtronic for replacement.

Comments on the draft guidance must be submitted by November 27, 2026. Facilities must comply with CGMP in accordance with specified enforcement policies to avoid potential enforcement actions.

Initiate the update of labeling materials for Rasonque to reflect the new FDA approval and ensure compliance with reporting requirements for newly approved therapies.

Healthcare professionals must include daraxonrasib in adverse event reporting as the new treatment option is now available for eligible patients.

Affected healthcare facilities should remove all Automated Impella Controllers from use and stock, ensure annual preventive maintenance is followed, and report any adverse reactions to Abiomed or MedWatch.

Facilities using these devices must immediately cease their use, segregate them from other stock, and return them to Boston Scientific. Relevant personnel must be notified of this recall.

Monitor and reassess affected pain and arthritis products, ensuring compliance with safety reporting protocols for products listed with known hidden ingredients.

Consumers should consult healthcare professionals if using this product and report any adverse effects to FDA’s MedWatch Safety Information.

Healthcare providers and manufacturers must now comply with new reporting obligations for adverse reactions associated with the use of Imaavy and ensure adherence to increased compliance requirements for its administration.

Regulatory intelligence teams should review ongoing studies and compliance with postmarketing requirements for the drugs listed, specifically focusing on their deadlines for completion and the nature of the studies required.

Stakeholders should incorporate the device authorization into labeling and signal management protocols to ensure compliance and effective communication regarding its capabilities.

Regulatory intelligence teams must update workflows to exclude clove oil as an anesthetic for fish and ensure compliance with the guidance, including awareness of approved alternatives.